EP08.02-097 Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina

Abstract

Between 20-35% of lung adenocarcinomas harbor KRAS gene mutations (KRASm). With the development of KRAS G12C covalent inhibitors as novel targeted therapies in this population, there is renewed interest in understanding the clinical features and outcomes of patients with KRAS mutant non-small cell lung cancer (NSCLC) worldwide.